ImaGenes to Offer Roche NimbleGen Micorarrays | GenomeWeb

NEW YORK (GenomeWeb News) – Genomics services provider ImaGenes has received certification from Roche NimbleGen to offer NimbleGen microarrays for chromatin immunoprecipitation (ChIP-chip) services, Roche NimbleGen said today.

Berlin-based ImaGenes passed a ChIP-chip certification using the NimbleGen Dual-Color workflow and the MS 200 Microarray Scanner to become a certified service provider. This certification enables ImaGenes to process samples for DNA-protein interactions and chromatin structure.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.